Liping Liu, HighTide Therapeutics CEO
January 5, 2023 05:00 AM EST
Financing
Startups
China

High­T­ide Ther­a­peu­tics rides NASH R&D wave with a $107M raise

Kyle LaHucik

Senior Reporter

High­T­ide Ther­a­peu­tics has raised a $107 mil­lion Se­ries C round to fund mid-stage stud­ies in meta­bol­ic and di­ges­tive dis­eases, with the goal of fil­ing for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times